USPTO serial 79210373
OPTHEA
Reviewed by CopyMark Law Group
Reg. 5477686Status 709
- Filing date
- Status date
- Registration date
- May 29, 2018
- Examiner
- THOMAS, JULIE
- Law office
- Historical data usage
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OPTHEA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard M. LaBarge
Richard M. LaBarge Marshall, Gerstein & Borun LLP233 South Wacker Drive, Suite 6300Chicago, IL 60606United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; [ Chemical preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; Chemical products, namely, sugars, proteins and nucleic acids for pharmaceutical use for the treatment of ophthalmic conditions; Chemicals for pharmaceutical use for the treatment of ophthalmic conditions; Pharmaceutical compositions for the treatment of ophthalmic conditions; Pharmaceutical creams for the treatment of ophthalmic conditions; Pharmaceutical drugs for the treatment of ophthalmic conditions; ] Pharmaceutical preparations for the treatment of ophthalmic conditions [ ; Pharmaceutical preparations for animals for the treatment of ophthalmic conditions; Pharmaceutical preparations for human use for the treatment of ophthalmic conditions; Pharmaceutical preparations for personal use for the treatment of ophthalmic conditions; Pharmaceutical preparations for veterinary use for the treatment of ophthalmic conditions; Pharmaceutical products for the treatment of ophthalmic conditions; Pharmaceutical products for use by humans for the treatment of ophthalmic conditions; Pharmaceutical substances for the treatment of ophthalmic conditions; Veterinary medicaments for the treatment of ophthalmic conditions; Veterinary preparations for the treatment of ophthalmic conditions; Veterinary products for the treatment of ophthalmic conditions; Biological preparations for medical purposes for the treatment of ophthalmic conditions; Biological preparations for use in biotechnology for the treatment of ophthalmic conditions; Biological preparations for use in cell cultures, namely in culture media for cultivating human, animal, plant or microorganism cells for medical use; Biological preparations for veterinary purposes for the treatment of ophthalmic conditions; Biological products for medical use, namely for the treatment of ophthalmic conditions; Biological reagents for use in molecular biology for medical use; Biological substances for medical use, namely, biologics, antibodies, monoclonal antibodies, cells and cellular tissues for medical use, namely for the treatment of ophthalmic conditions; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Chemical products, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for use in biology for medical or veterinary use, namely for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Therapeutic biological products, namely, biologics, antibodies, monoclonal antibodies, cells and cellular tissues for medical use, namely for the treatment of ophthalmic conditions; Medical preparations for the treatment of ophthalmic conditions; Substances for use in genetic probe assay kits for medical use, namely, medical diagnostic reagents and assays for testing body fluids; Substances for veterinary use produced by genetic engineering, namely, genetically engineered tissues for transplant purposes; Cultures of cell media for medical use; Cultures of cell media for veterinary purposes; Chemical products for medical or veterinary laboratory use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical preparations for medical analysis purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical preparations for medical purposes for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical preparations for veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for analysis for medical purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for analysis for veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for biotechnological purposes for medical uses, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for biotechnological purposes for veterinary use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for medical or veterinary diagnostic purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical diagnostic use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for veterinary diagnostic use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for use in medical science, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for use in science for medical or veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemicals for use in medical and veterinary analysis , namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions ] | SECTION 71 - CANCELLED | — |
| 042 | [ Advisory services relating to scientific research; Laboratory services, namely, scientific research or analysis in the field of ophthalmology; Management of scientific research projects; Medical research and scientific research for medical purposes; Preparation of reports relating to scientific research; Preparation of scientific reports; Providing information, including online, about scientific and technological services and research and design relating thereto, namely for scientific research, analyses and testing in the field of ophthalmology; Provision of information relating to scientific research; Provision of scientific information in the field of ophthalmology; Scientific advisory services in the field of ophthalmology; Scientific analysis in the field of ophthalmology; Technical analysis for research and testing in the field of ophthalmology; Scientific and technological services namely for scientific research, analysis and testing in the field of ophthalmology; Scientific consultancy relating to ophthalmic conditions; Scientific laboratory services; Scientific research; Scientific research in the field of pharmacy; Scientific research into the development of new products; Scientific research relating to bacteriology; Scientific research relating to biology; Scientific research relating to chemical products; Scientific research relating to chemistry; Scientific research relating to genetics; Scientific testing services in the field of ophthalmology; Bacteriological research; Biochemistry research services; Biological research; Biotechnological research; Biotechnology research; Chemical research; Chemical technological research; Genetic research; Laboratory research; Medical research; Pharmaceutical research services; Providing information, including online, about industrial analysis and research services namely for scientific research, analyses and testing in the field of ophthalmology; Provision of medical, veterinary, biological and pharmaceutical research services in the field of ophthalmology; Research and development of new products for others; Research and development of products; Research into the development of new products; Research laboratories in the field of ophthalmology; Research relating to bacteriology; Research relating to biotechnology; Research relating to chemicals; Research relating to chemistry; Research relating to medicine; Research relating to molecular sciences; Research relating to pharmaceuticals; Research relating to science; Research to develop new products; Services for assessing the efficiency of pharmaceuticals namely pharmaceutical product evaluation; Services for assessing the safety of pharmaceuticals, namely testing, inspection or research of pharmaceuticals; Chemical analysis; Laboratory analysis in the field of ophthalmology; Analysis of tissues for medical research; Design of medical apparatus; Medical laboratory services; Analytical laboratory services, namely analysis of tissue samples or bodily fluids for diagnostic purposes; Chemical laboratory services; Laboratory testing services, namely testing of tissue samples or bodily fluids for diagnostic purposes; Veterinary laboratory services; Information in the field of chemical research; Testing of chemicals ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Opthea Limited
- Other trademarks owned by Opthea Limited
- Other trademarks owned by Opthea Limited
- Other trademarks owned by Ceryvyn Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named OPTHEA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 10, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 17, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 10, 2026 | NC71 | NOTICE OF CANCELLATION SEC. 71 E-MAILED | — |
| Feb 10, 2026 | C71T | CANCELLED SECTION 71 | — |
| Jul 28, 2025 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Jul 7, 2025 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Jan 4, 2025 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Dec 26, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 22, 2024 | ES71 | TEAS SECTION 71 RECEIVED | — |
| May 29, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 15, 2022 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Dec 3, 2022 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Jan 2, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 28, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 12, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 12, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 29, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 29, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 13, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 13, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 9, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 21, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 21, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 21, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 6, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 9, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 8, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 8, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 28, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 6, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 6, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 30, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 29, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 27, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 23, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 23, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 22, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |